Page 124 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 124
Liver Transplantation / Surgery: Clinical
P0025 THE PUBLIC HEALTH VALUE OF SPARING LIVERS FOR
TRANSPLANTATION THROUGH SYSTEMATIC TREATMENT
OF HEPATITIS C
Warren Stevens,Yuri Sanchez, Ron Brookmeyer, Darius Lakdawalla,
Steve Marx PharmD, Timonthy Juday *, The United States
P0026 THE HIV INFECTION DOES NOT HAVE IMPACT
ON SURVIVAL AND TUMOR RECURRENCE IN
HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY
LIVER TRANSPLANTATION
Fernando Agüero, Alejandro Forner*, Christian Manzardo,
Andrés Valdivieso, Marino Blanes, Rafael Barcena, Antoni Rafecas,
Lluis Castells, Antoni Rimola, Jose M. Miró, Spain
P0027 COST-EFFECTIVENESS OF PRE-TRANSPLANT
SOFOSBUVIR TO PREVENT RECURRENCE OF HCV
INFECTION AFTER LIVER TRANSPLANTATION
Alessandro Vitale*, Gaya Spolverato, Patrizia Burra, Umberto Cillo,
Stefano Fagiuoli, Italy
ePOSTERS P0029 ACTIVE IMMUNIZATION IN PREVENTION OF DE
NOVO HEPATITIS B IN ADULT LIVING DONOR LIVER
TRANSPLANTATIONWITH CORE ANTIBODY POSITIVE GRAFT
Poh Yen Loh*, Chih Che Lin, Chao Long Chen, Singapore
P0030 UTILITY BASED CRITERIA TO SELECT PATIENTS
WITH HEPATOCELLULAR CARCINOMA FOR LIVER
TRANSPLANTATION: A MULTICENTRE COHORT STUDY
Alessandro Vitale*, Fabio Farinati, Franco Trevisani, Patrizia Burra,
Edoardo G. Giannini, Gaya Spolverato, Umberto Cillo, Italy
P0031 FREQUENCY AND OUTCOMES OF SIMULTANEOUS LIVER
KIDNEY TRANSPLANTATION IN NASH
Ashwani K. Singal*, Mohsen Hasanin, Mohamed Kaif,Yong-Fang Kuo,
Russell Wiesner, The United States
P0032 THE IMPACT OF ISCHEMIA/REPERFUSION INJURY ON
LIVER ALLOGRAFTS FROM DECEASED AFTER CARDIAC
DEATH VERSUS DECEASED AFTER BRAIN DEATH DONORS
Blayne Amir Sayed, Jin Xu, Ana Maria Casas-Ferreira, Parthi Srinivasan,
Nigel Heaton,Yun Ma, Cristina Legido-Quigley, Susan Fuggle,
Wayel Jassem*, The United Kingdom
124 The International Liver Congress™ 2015 • ILC Programme
P0025 THE PUBLIC HEALTH VALUE OF SPARING LIVERS FOR
TRANSPLANTATION THROUGH SYSTEMATIC TREATMENT
OF HEPATITIS C
Warren Stevens,Yuri Sanchez, Ron Brookmeyer, Darius Lakdawalla,
Steve Marx PharmD, Timonthy Juday *, The United States
P0026 THE HIV INFECTION DOES NOT HAVE IMPACT
ON SURVIVAL AND TUMOR RECURRENCE IN
HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY
LIVER TRANSPLANTATION
Fernando Agüero, Alejandro Forner*, Christian Manzardo,
Andrés Valdivieso, Marino Blanes, Rafael Barcena, Antoni Rafecas,
Lluis Castells, Antoni Rimola, Jose M. Miró, Spain
P0027 COST-EFFECTIVENESS OF PRE-TRANSPLANT
SOFOSBUVIR TO PREVENT RECURRENCE OF HCV
INFECTION AFTER LIVER TRANSPLANTATION
Alessandro Vitale*, Gaya Spolverato, Patrizia Burra, Umberto Cillo,
Stefano Fagiuoli, Italy
ePOSTERS P0029 ACTIVE IMMUNIZATION IN PREVENTION OF DE
NOVO HEPATITIS B IN ADULT LIVING DONOR LIVER
TRANSPLANTATIONWITH CORE ANTIBODY POSITIVE GRAFT
Poh Yen Loh*, Chih Che Lin, Chao Long Chen, Singapore
P0030 UTILITY BASED CRITERIA TO SELECT PATIENTS
WITH HEPATOCELLULAR CARCINOMA FOR LIVER
TRANSPLANTATION: A MULTICENTRE COHORT STUDY
Alessandro Vitale*, Fabio Farinati, Franco Trevisani, Patrizia Burra,
Edoardo G. Giannini, Gaya Spolverato, Umberto Cillo, Italy
P0031 FREQUENCY AND OUTCOMES OF SIMULTANEOUS LIVER
KIDNEY TRANSPLANTATION IN NASH
Ashwani K. Singal*, Mohsen Hasanin, Mohamed Kaif,Yong-Fang Kuo,
Russell Wiesner, The United States
P0032 THE IMPACT OF ISCHEMIA/REPERFUSION INJURY ON
LIVER ALLOGRAFTS FROM DECEASED AFTER CARDIAC
DEATH VERSUS DECEASED AFTER BRAIN DEATH DONORS
Blayne Amir Sayed, Jin Xu, Ana Maria Casas-Ferreira, Parthi Srinivasan,
Nigel Heaton,Yun Ma, Cristina Legido-Quigley, Susan Fuggle,
Wayel Jassem*, The United Kingdom
124 The International Liver Congress™ 2015 • ILC Programme
